A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer
Clinical Colorectal Cancer · 2022-09 · 21 (3) · 252-258
DOI: 10.1016/j.clcc.2022.05.004 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Colorectal Cancer, 2022-09. Verfasst von Jeremy Chuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Trifluridine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corp, Novartis.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: We conducted a phase I study to evaluate the maximum tolerated dose (MTD), safety, and efficacy of trametinib in combination with TAS-102 in patients with chemotherapy-refractory KRAS-mutant, wild-type PIK3CA/PTEN metastatic colorectal cancer (mCRC). METHODS: A 3+3 dose de-escalation single arm phase I clinical trial was performed in patients with chemorefractory mCRC without priorTAS-102 exposure. Patients received fixed dosing of trametinib 2mg oral daily along with de-escalating doses of TAS-102 beginning at 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 days. Primary endpoint was evaluation of MTD. RESULTS: 25 eligible patients were enrolled in this study. During the dose de-escalation phase, no dose-limiting toxicities (DLT) were observed at the full doses of trametinib/TAS-102 and the MTD was determined to be TAS-102 35 mg/m2 orally twice daily on days 1 to5 and days 8 to12 every 28 days with continuous trametinib dosing at 2mg orally daily. No patients achieved a partial or complete response. 5 of 21 evaluable patients (23.81%) achieved a stable disease response. Median PFS was two months (95% confidence interval [CI] 1.70-4.82) while median OS was 7 months (95% CI 6.36-11.48). Treatments were well tolerated with most common grade ≥ 3 adverse events being anemia (20%), neutropenia (12%), leukopenia (8%), diarrhea (8%), rash (4%), and fatigue (4%). CONCLUSIONS: Trametinib in combination with TAS-102 demonstrated a manageable safety profile. However, this combination did not achieve meaningful clinical benefit in patients with RAS-mutated PIK3CA and PTEN wild-type refractory mCRC. CLINICAL TRIAL INFORMATION: NCT03317119.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
- Department of Biostatistics, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA.
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA. Electronic address: mfakih@coh.org.
Förderung
- Novartis Pharmaceuticals Corp
- Novartis
Zitieren
APA
Chuang, J., Gong, J., Li, S. M., Wang, C., & Fakih, M. (2022). A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 21(3), 252-258. https://doi.org/10.1016/j.clcc.2022.05.004
Vancouver
Chuang J, Gong J, Li SM, Wang C, Fakih M. A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 2022;21(3):252-258. doi:10.1016/j.clcc.2022.05.004
BibTeX
@article{Chuang2022,
author = {Chuang, Jeremy and Gong, Jun and Li, Sierra Min and Wang, Chongkai and Fakih, Marwan},
title = {A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer},
journal = {Clinical Colorectal Cancer},
year = {2022},
volume = {21},
number = {3},
pages = {252--258},
doi = {10.1016/j.clcc.2022.05.004}
}
EUVIMED